Gilead’s Descovy Earns FDA Approval

The FDA has approved Gilead Sciences’ combination therapy Descovy for the treatment of HIV-1 infection in adults and pediatric patients.

Indicated for use with other antiretroviral agents in patients 12 and older, the drug is a combination of emtricitabine and tenofovir alafenamide F/TAF. Descovy earned a positive recommendation from the European Medicines Agency in February.

Descovy carries a boxed warning on the risks of lactic acidosis/severe hepatomegaly with steatosis and post-treatment acute exacerbation of hepatitis B.